CORALVILLE, Iowa--(BUSINESS WIRE)--Global genomics solutions provider, Integrated DNA Technologies (IDT), is bringing a new solution to address challenges researchers face in accelerating Human Immunodeficiency Virus (HIV) drug discovery and research. The company announced availability of the xGen HIV Amplicon Panel consisting of primers designed to cover 99.3% of the HIV genome. Powered by IDT’s xGen Amplicon Technology, the HIV panel provides a single-tube, two-step PCR amplification workflow that uses overlapping primer sets to obtain high levels of genome coverage from as low as 1,000 double-stranded viral genome copies.
“This launch represents one of the many ways IDT is continuing to innovate on its NGS portfolio, comprised of stand-alone library preparation, target enrichment, and normalization chemistries, as well as connected NGS solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms and drug development research,” said Steven Henck, PhD, Vice President, R&D at Integrated DNA Technologies. “While the scientific community has learned a lot about HIV and the disease it causes, continued research is needed to help the millions of people whose health continues to be threatened by the global HIV/AIDS pandemic. We believe our xGen HIV Amplicon Panel provides an accessible option for researchers and will be foundational to unlocking future discoveries and advancing HIV research.”
IDT’s xGen HIV Amplicon Panel offers a streamlined workflow that goes from sample to sequencer in 2.5 hours with up to 1536 unique dual indexing primers (UDIs) for multiplexed sequencing. This predesigned xGen Amplicon Panel built with xGen Amplicon Technology includes amplicon tiling and creation of super amplicons to ensure comprehensive genome coverage across existing variant genomes and provide resistance to future viral mutations that may fall within a priming site, thus enabling future identification of novel variants.
To learn more or order IDT’s xGen HIV Amplicon Panel, visit idtdna.com/ngsHIV.
About IDT
For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has empowered genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, featuring the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.
Seeking to fulfill its mission of accelerating the pace of genomics, IDT acquired Archer™ NGS Research Assays in December 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.
IDT’s infrastructure supports customers around the globe with its manufacturing headquarters situated in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Boulder, Colorado, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.
IDT is proud to be part of Danaher. Danaher’s science and technology leadership puts IDT’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.
Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. RUO24-2923_001
